EDAP TMS S.A. reported second quarter 2026 financial results for its continuing HIFU operations, which generated $13.2 million in revenue, a 39% increase year-over-year. The company sold 13 Focal One systems and grew U.S. procedure volume by 47%. Gross margin improved to 55.6%, while operating expenses rose to $15.4 million due to rebranding costs. The net loss was $14.4 million, or ($0.38) per share, primarily driven by a $5.5 million warrant valuation impact. Cash and cash equivalents totaled $21.5 million. Management reiterated 2026 revenue guidance of $50.0 to $54.0 million. Additionally, the company announced an underwritten public offering for $40 million in gross proceeds expected to close on August 14, 2026. EDAP TMS S.A. operates in the medical device industry, developing and marketing minimally invasive robotic focal therapy systems.
